Kidney Week

Educational Symposium

HIF-PH Inhibitors: Moving Beyond Erythropoietin and Iron Deficiency

October 24, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors are the first novel class of medications to treat anemia since the approval of erythropoietin-stimulating agents in 1989. HIF-PH inhibitors are oral agents that treat anemia of CKD through multiple pathways; they have effects on inflammation and iron handling and decrease hepcidin levels. Advantages of HIF-PH inhibitors include decreased erythropoietin levels, increased absorption of oral iron, and access to existing iron stores.

Results of Phase 3 trials of HIF-PH inhibitors for the treatment of anemia in both dialysis-dependent and non–dialysis-dependent CKD have been promising. This symposium discusses the results of clinical trials and provides recommendations on the role of HIF-PH inhibitors in managing anemia of CKD.

Support is provided by an educational grant from Akebia Therapeutics, Inc. and Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

• Compare the advantages and disadvantages of HIF-PH inhibitors with those of erythropoietin-stimulating agents for the management of anemia in CKD
• Determine the place for HIF-PH inhibitors in the management of anemia in CKD

Learning Pathway(s)

• Bone and Mineral Metabolism
• Chronic Kidney Disease

Moderator

• Jeffrey S. Berns, MD, FASN

Presentations

• Introduction
  01:00 PM - 01:10 PM
  Jeffrey S. Berns, MD, FASN
  
  Jeffrey S. Berns, MD, FASN

Introduction

October 24, 2020 | 01:00 PM - 01:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Non-Dialysis-Dependent CKD
  01:10 PM - 01:35 PM
  Francesco Locatelli, MD
  
  Francesco Locatelli, MD

Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Non-Dialysis-Dependent CKD

October 24, 2020 | 01:10 PM - 01:35 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Dialysis-Dependent CKD
  01:35 PM - 02:00 PM
  Kai-Uwe Eckardt, MD 
  
  

  Kai-Uwe Eckardt, MD

  Kai-Uwe Eckardt is Professor of Medicine and Head of the Department of Nephrology and Medical Intensive Care at the Charité in Berlin, Germany. Prior to taking this position in April 2017 he was Chair of Nephrology and Hypertension at the University of Erlangen-Nürnberg, where he also served as Vice Dean for Research and International Affairs. Dr. Eckardt's major scientific interests lie in the molecular mechanisms and relevance of oxygen sensing and the development of acute and chronic renal injury. He chaired a Collaborative Research Centre (CRC) on kidney injury at the University of Erlangen-Nürnberg and is currently vice spokesperson of the CRC 1365 "Renoprotection" at the Charité. He is also principal investigator of the German Chronic Kidney Disease (GCKD) study, the largest CKD cohort study worldwide. Dr. Eckardt is a member of review panels of the German Research Foundation and has served on several international scientific advisory boards. He has also served in various capacities for international organizations, including terms as council member of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), councillor and executive councillor of the International Society of Nephrology (ISN), chair of the ISN Forefront Committee, program chair of the World Congress of Nephrology 2009 and 2017 and founding executive committee member and past co-chair of the organization Kidney Disease: Improving Global Outcomes (KDIGO).

Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Dialysis-Dependent CKD

October 24, 2020 | 01:35 PM - 02:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.